Warning Letter Recipients Can Get ‘Closeout Letters’ From FDA

Clinical Trials Advisor
Sponsors or investigators that have resolved issues in warning letters from the FDA dated Sept. 1 or later — and have passed inspections that verify the corrective action — are eligible for closeout letters.

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $10.00